UCB to double staff at Swiss biopharma plant; Merck agrees to settle NY, FL Vioxx claims;

 @FiercePharma: Bloomberg's take on Multaq's failure in that permanent AF study: Sanofi med doubled risk of death pharma $SNY. News | Follow @FiercePharma

> Belgium's UCB said it would double its workforce at a bioproduction facility in Bulle, Switzerland, to 400 from 200 by the time it opens in 2015. Report

> Merck ($MRK) has agreed to settle claims from New York and Florida, which had alleged that the company failed to adequately disclose the risks of its now-withdrawn painkiller Vioxx. News

> Amgen ($AMGN) said EU regulators approved new uses for its Vectibix drug in combination with chemotherapy in colorectal cancer patients; previously the treatment was approved as monotherapy. Amgen release

> China's drug regulator has begun inspecting overseas manufacturing facilities as the proportion of imported medicines grows along with its domestic pharma market. Story

> The American Medical Association voted to back legislation designed to ease ongoing shortages of key drugs. Release

> Sun Pharmaceuticals protested the Indian government's new pricing policy, saying that it could lead to shortages of key drugs. Article

> Sinclair IS Pharma sold its tremor drug Mysoline to France's Laboratoires Serb for ₤11.1 million ($17.6 million). Piece

> ThermalTherapeutic Systems has tapped a new president and CEO, Gardiner Smith, to lead the launch of its product Veratherm, which won FDA approval last year. News

> Singapore's Invida bought the dermatology brand portfolio of India's Shalaks Pharmaceuticals, including anti-acne, anti-fungal and anti-scar topical treatments, along with other products. Report

Biotech News

 @FierceBiotech: Special worms win over mice as Parkinson's drug tool. Article | Follow @FierceBiotech

 @JohnCFierce: There's no way to sugarcoat it. Geron's decision to abandon ESC work is a major setback for the field. Going to China? News | Follow @JohnCFierce

 @RyanMFierce: With Alex Denner leaving Icahn's group, does he resign from biotech boards he sits on through Icahn-backed campaigns? | Follow @RyanMFierce

 @MaureenFierce: FDA says Pfizer's best-selling Prevnar vaccine is comparable to Merck's vaccine. Story | Follow @MaureenFierce

> Icahn biotech whiz Denner jumps ship after 5 turbulent years. Story

> Geron abandons pioneering stem cell program, lays off 66. News

Biotech Research News

> A possible way to stop a tumor from spreading: Look inside. Story

> Ziopharm goes organic for potential prostate cancer treatment. Report 

> Special worms win over mice as Parkinson's drug tool. Item

> Drug cuts off fat-tissue blood supply in monkeys and mice. Story

Manufacturing News

> IMS advises risk-based warning system for drug shortages. Item

> Booz offers 5 steps to reinvent supply chain. Report

> Five die in pharma plant fire. News

> FDA visits Indian plant after meningitis outbreak. Article

> Pfizer transforms manufacturing for 'dynamic market.' Story

> AMA counts to 10 before voting drug shortages position. News

And Finally... Smugglers are bringing an older version of the often-abused painkiller OxyContin into the U.S. from Canada. Report

Suggested Articles

Regeneron and Sanofi hope their PD-1 inhibitor Libtayo will be the first immuno-oncology treatment approved to treat basal cell carcinoma.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

Pfizer, GSK, BIO and others are all planning vaccine messages for fall.